Each mouse was challenged intranasally (i.n).n
Each mouse was challenged with a mixture of 5×106 pRBC containing an equal proportion of blood stage parasites, CB and AJ.
After recording baseline values, each mouse was challenged with an aerosol of methacholine, generated with an in-line nebulizer and administered directly through the ventilator for 5 seconds delivering increasing concentrations (0, 0.625, 1.25, 2.5, 5, and 10 mg/ml).
Briefly, groups of Balb/c mice were given a single 2-mg/kg intraperitoneal injection of H3H, F4H, F3A or dimethyl sulfoxide as a control and, after 30 minutes, each mouse was challenged intraperitoneally with BoNTA at 5 times of its median-lethal dose.
Groups of Balb/c mice were given one 2-mg/kg intraperitoneal injection of H3H, F4H, F3A, or dimethyl sulfoxide as a control and, after 30 minutes, each mouse was challenged intraperitoneally with BoNTA at 5 times of its median-lethal dose.
Each mouse was challenged with HSV-2 MS on Day 80, and the reduction in HSV-2 MS vaginal shedding from an individual mouse was calculated as y = Δlog (pfu/vagina) = 5.20 log10 pfu/vagina (mean naïve titer) – HSV-2 titer shed from this mouse (Fig. 5D).
Seven days P.I. a footpad of the immunized mice was challenged with an intradermal injection of IRBP peptide.
As a control, a group of untreated MRL/lpr mice was challenged in parallel.
However, selecting appropriate markers of such cells in mice was challenging.
Both male and female DBA/1 mice and DBA/1.IL-1R1−/− mice were challenged with anti-GBM sera.
C57BL/6J mice were challenged with six doses of engineered toxins via intraperitoneal (I.P).
